|
FY2026
12 months to Mar 31, 2026
|
FY2025
12 months to Mar 31, 2025
|
FY2024
12 months to Mar 31, 2024
|
|
|---|---|---|---|
| Expenses | |||
| Sales and marketing | |||
| Research and development | |||
| General and administrative | |||
| Professional and consulting fees | |||
| Loss before other items | |||
| Other items | |||
| Other income | |||
| Other expense | |||
| Depreciation | |||
| Interest income | |||
| Interest expense | |||
| Foreign exchange loss | |||
| Listing expense | |||
| Transaction expense | |||
| Gain on debt settlement | |||
| Fair value gain/(loss) on convertible note | |||
| Fair value gain/(loss) on warrant liability | |||
| Fair value gain/(loss) on promissory notes | |||
| Fair value loss on warrant exchange | |||
| Fair value gain on investment in Psyence Labs Ltd | |||
| Fair value loss on digital assets | |||
| Share of losses from Associate | |||
| NET INCOME/(LOSS) | |||
| Other comprehensive income/(loss) | |||
| Foreign exchange gain/(loss) on translation | |||
| Other comprehensive income | |||
| TOTAL COMPREHENSIVE LOSS | |||
| TOTAL COMPREHENSIVE INCOME/(LOSS) | |||
| Income/(Loss) per share - basic (in Dollars per share) | |||
| Income/(Loss) per share - diluted (in Dollars per share) | |||
| Weighted average number of outstanding shares - basic (in Shares) | |||
| Weighted average number of outstanding shares - diluted (in Shares) |
Loading...
